Rare disease day takes place on February 28th of each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Finding the best amyloidosis care is not easy, so in 2017 ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. Now MAP can do even more. (more…)
The 2018 annual meeting of the American Society of Hematology (ASH) featured the latest scientific updates, including advances in treatment and new insights in amyloidosis. (more…)
NICE issue initial negative decisions on inotersen and patisiran
The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC Talks Webinar, Dr. Nelson Leung focused on renal involvement in AL, AA, ALECT2 and ATTR amyloidosis, while discussing treatment and response assessments for each type.
Original Presentation Date:
August 21, 2023
Key Webinar Highlights:
0:00 — Introduction
2:30 — Start of presentation
3:03 — Kidney involvement in AL amyloidosis
15:30 — Kidney involvement in in AA amyloidsis
20:34 — Kidney involvement in in Alect-2
24:37 — Kidney involvement in wild type amyloidosis
30:34 — Kidney transplants for amyloidosis patients